DISCOUNT ZERTIFIKAT - NOVO NORDISK ADR B | Real-time Bid/Ask 10:58:06 2024-07-03 EDT | ||
| 111.13 EUR / 111.15 EUR | -1.25% |
|
| Current month | -0.72% | ||
| 1 month | +3.98% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-07-03 | 111.8 | -0.67% |
| 24-07-02 | 112.6 | -1.11% |
| 24-07-01 | 113.8 | +0.39% |
| 24-06-28 | 113.4 | +0.16% |
| 24-06-27 | 113.2 | -0.24% |
Delayed Quote Börse Stuttgart
Last update July 03, 2024 at 06:31 am
More quotesStatic data
| Product type | Discount Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | ME8V92 |
| ISIN | DE000ME8V927 |
| Date issued | 2024-02-16 |
| Maturity | 2025-06-20 (352 Days) |
| Parity | 1 : 1 |
| Emission price | 104.2 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 114.6 € |
|---|---|
| Lowest since issue | 99.25 € |
| Spread | 0.02 € |
| Spread % | 0.02% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
993.5
DKK
Average target price
952.2
DKK
Spread / Average Target
-4.16%
- Stock Market
- Certificates
- Certificat
